PMS2 and colorectal carcinoma: The incidence of malignancies is reported to be much lower in PMS2 mutation carriers (cumulative lifetime risk has been estimated at 18.75% in males and 10.56% in females for CRC and 11.78% for EC at age 70 [22]) compared to the other MMR genes [20].